OBJECTIVES: The Spanish Joint Committee for New Drugs Evaluation (JCNDE) was created in 2003 and is formed by 5 Regional Drug Evaluation Centres. JCNDE has common Standard Operating Procedures (SOPs) to unify drug assessments and where the comparators availability is a key issue. Each individual Drug Evaluation Centre has its own new drug therapeutic bulletin to spread information between their health professionals. The objective of this study was to quantify the uniformity degree through the drug bulletins and the degree of heterogeneity reflected in the drug costs. METHODS: New drug therapeutic bulletins of the 5 members of the JCNDE were reviewed between 2006-2009. Each drug assessed by the JCNDE was tracked to identify which members reported it in their bulletins. Comparative drugs included in the bulletins were also registered to find potential heterogeneity amongst the JCNDE members. Daily/monthly treatment costs described were included in the study database.  RESULTS: Fifty-seven drug evaluations were recorded, forty (70%) were published by at least 3 members of the JCNDE, and only 12 were published by all of them. Andalusia, Basque Country and Catalonia are the most active members, with 12-14 new drugs published per year. In all the bulletins were identified some differences in the comparators used for each new drug assessed. Andalusia and Catalonia tend to include more comparators. The highest level of heterogeneity is observed in drugs of diabetes treatment. Most of the drug costs reported were very similar. Only one disagrement between the JCNDE was identified in the drug innovation rating. CONCLUSIONS: JCNDE has made advances to unify drug assessment in Spain. Nevertheless, health-economics arguments are still focused on drug treatment cost comparisons. The comparators found in the drug bulletins are slightly different amongst the regions. Future SOPs version ought to improve these two weak points.